A retrospective evaluation of 200 consecutive recipients of autologous peripheral blood stem cell transplantation (PBSCT) was conducted to ascertain the incidence, risk factors, clinical features, complications, and outcome of cytomegalovirus (CMV) infection. A total of 26 patients (13%) developed CMV viremia (n = 5), DNAemia (n = 3), viruria (n = 18) and/or disease (n = 3) at a median of 45 days following stem cell infusion. None of the patients underwent surveillance testing for CMV. A diagnosis was established by culture and polymerase chain reaction of blood, urine or other tissue samples submitted when patients exhibited clinical features suggestive of CMV infection. Cytomegalovirus seropositivity prior to transplantation was the only statistically significant risk factor predicting subsequent identification of CMV (P Ͻ 0.001). The symptoms were severe enough in 23 patients to warrant treatment with intravenous ganciclovir. Three patients developed CMV disease; two developed fatal CMV pneumonia and one developed CMV gastritis which responded to antiviral treatment. Clinical signs and symptoms as well as viremia and viruria resolved with (20 patients) and without (three patients) treatment in the remaining individuals. All instances of CMV viremia, DNAemia, viruria and disease occurred within 3 months of stem cell infusion. These results demonstrate that CMV is a common pathogen after autologous PBSCT and may result in fatality in rare instances. Surveillance programs appear to be neither useful nor cost-effective. Diagnostic evaluation should be performed only in patients exhibiting suspicious clinical features and antiviral chemotherapy should be administered for persistent and severe signs and symptoms.
viruria have been associated with an increased risk of CMV disease. [1] [2] [3] Recent advances in diagnostic techniques have enabled earlier detection of the virus. 4 Furthermore, the use of ganciclovir as prophylactic, 5, 6 pre-emptive, [7] [8] [9] or definitive therapy 10 has reduced mortality rates. Cytomegalovirus is also a major opportunistic pathogen in the autologous BMT setting although mortality is much lower than in allogeneic BMT recipients. 11 Very few studies of CMV viremia, viruria, DNAemia and disease have been reported following autologous peripheral blood stem cell transplantation (PBSCT). [12] [13] [14] [15] [16] We evaluated 200 consecutive recipients of autologous PBSCT in order to ascertain the incidence, risk factors, clinical manifestations, complications and outcome of CMV viremia, viruria, DNAemia and disease. All previously reported studies of CMV viremia and disease in such patients have been based on a variety of surveillance programs. [11] [12] [13] [14] [15] [16] [17] [18] Some investigators believe that surveillance is unnecessary in patients undergoing autologous transplantation because of a low likelihood of complications. 14 Moreover, surveillance studies can be expensive and timeconsuming. Our study is unique because none of the patients underwent surveillance for CMV, and the virus was identified by laboratory studies performed only when individuals presented with suspicious clinical findings.
Patients and methods
Two hundred consecutive patients underwent autologous PBSCT between March 1993 and August 1996, at the University of Connecticut Health Center, Farmington, CT, and were eligible for retrospective evaluation. Clinical data were obtained from comprehensive chart reviews (Table 1) .
Underlying malignancies included carcinoma of the breast (n = 99), non-Hodgkin's lymphoma and Hodgkin's disease (n = 65), multiple myeloma (n = 14), ovarian cancer (n = 7), acute leukemia (n = 6), and miscellaneous solid tumors (n = 9). Myeloablative chemotherapy regimens consisted of either busulfan 16 mg/kg orally, carboplatin 800-1000 mg/m 2 intravenously, and thiotepa 500-700 mg/m 2 intravenously (BUCAT) (n = 126), or busulfan 16 mg/kg orally, cyclophosphamide 90 mg/kg intravenously, and etoposide 60 mg/kg intravenously (BUCET) (n = 69). Five patients received other regimens. Previously collected and cryopreserved autologous peripheral blood stem cells were infused on day zero. Acyclovir 250 mg/m 2 intravenously every 8 h was administered from the initiation of myelo- ablative chemotherapy until engraftment (absolute neutrophil count greater than 1 ϫ 10 9 /l) in patients who were sero-positive for Herpes simplex (n = 126). Subsequently, these patients received acyclovir orally 400 mg twice daily until 50 days after stem cell infusion. Methylprednisolone, initially 0.5 mg/kg intravenously or orally, was administered for 6 weeks in tapering doses, beginning 2 days after stem cell infusion. Regardless of CMV serologic status, all individuals received CMV sero-negative blood products.
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Due to the retrospective nature of this analysis and the absence of surveillance for CMV, a practical definition of presumptive disease had to be utilized initially based on certain CMV-associated symptoms. 19 Some of these clinical features have been used previously, 20 and additional ones were also utilized in this study. The CMV-associated symptoms included unexplained fever, persistent respiratory and gastrointestinal symptoms of unclear etiology, hemorrhagic cystitis, new onset of elevated hepatic transaminases beyond 4 weeks from stem cell infusion, unexplained thrombocytopenia of new onset, reversal of neutrophil/lymphocyte ratio, unexplained fluid retention, and unexplained constitutional symptoms (lethargy, fatigue, malaise, arthralgia and anorexia of recent onset). The total number of diagnostic tests performed in response to each of these signs and symptoms was determined and the positive predictive value of each clinical feature was ascertained.
Viremia was defined as the detection of CMV from blood by culture. 19, 20 DNAemia was defined as the detection of CMV in blood by polymerase chain reaction (PCR). Viruria was defined as the detection of viral excretion in the urine by culture. Cytomegalovirus disease required the presence of signs and/or symptoms related to the affected organ along with detection of the virus from that organ. 19, 20 Pneumonia required radiographic abnormalities and/or hypoxemia along with the detection of CMV in broncho-alveolar lavage or lung biopsy specimens. Gastrointestinal disease required clinical symptoms along with the presence of CMV demonstrated by histology or immune histochemistry in biopsies obtained from macroscopic lesions in the gastrointestinal tract. Samples of blood, urine or other relevant tissue were submitted for analysis. The pH of the clean catch urine was adjusted to 7.0 with 1 n NaOH or 1 n HCl prior to shell vial, tube culture or PCR testing. Blood sample for shell vial and conventional culture was collected in a heparin tube. Blood sample for PCR was collected in an EDTA tube. Buffy coats were separated from 5-7 ml of each blood sample using Ficoll-Hypaque (M-PRM) (ICN Biomedicals, Aurora, OH, USA) according to the manufacturer's protocol and were resuspended individually in 1 ml of minimal essential medium (MEM) with 2% fetal bovine serum (FBS).
For conventional tube culture, human diploid cells (Viromed Laboratories, Minneapolis, MN, USA) were inoculated with 0.3 ml of each specimen and maintained for 4 weeks at 35°C and were examined daily for the first 2 weeks and twice weekly for the next 2 weeks for CMV cytopathic effect.
Shell vials containing MRC-5 (Viromed) were inoculated with 0.3 ml of each specimen and centrifuged at 700 g for 40 min. Afterwards, 2 ml of MEM with 2% FBS, penicillin, streptomycin, and gentamicin was added to each vial and incubated in a CO 2 incubator at 35°C for 24 h. After incubation, the medium of the shell vial was removed by aspiration and the cover slip was washed twice with phosphatebuffered saline (pH 7.2) and fixed with acetone for 10 min. The indirect immunofluorescence staining was done on the cover slips according to the manufacturer's protocol (Chemicon International, Pemecula, CA, USA).
DNA was extracted from 100 l of urine or leukocytes using IsoQuick nucleic acid extraction kit (ORCA Research Bothell, WA, USA) according to the manufacturer's protocol. The extracted DNA was resuspended in 20 l of nuclease-free water. Five microliters of this suspension was subjected to 45 cycles of PCR amplification.
PCR was carried out in 0.2 ml microcentrifuge tubes in a Gene Amp PCR system 9600 thermal cycler (Perkin Elmer, Norwalk, CT, USA). The PCR target was a 249 bp sequence unique to CMV immediate early antigen. The primer pair used were CMV 1 sense 5Ј-CCT AGT GTG GAT GAC CTA CGG GCC A-3Ј and CMV2 antisense 5Ј-CAG ACA CAG TGT CCT CCC GCT CCT C-3Ј both at a concentration of 50 pm. PCR reaction mix contained 5 l of 10 ϫ PCR buffer (100 mm Tris-HCl (pH 8.3), 500 mm KCl, 25 mm MgCl 2 , 0.001% (wt/vol) gelatin), 200 m each deoxynucleotidetriphosphate, 2.5 U Taq polymerase (Perkin Elmer) and water to yield a 50 l reaction volume per tube. The tubes were inoculated with 5 l of extracted DNA and subjected to 45 cycles at 94°C for 30 s, 55°C for 30 s and 72°C for 60 s. PCR products were electrophoresed and visualized in an ethidium bromide stained 3% agarose gel (FMC Bioproducts, Rockland, ME, USA). The amplicons were then blotted on to nylon membrane, and probed with an alkaline phosphatase-conjugated chemiluminescent probe (Lightsmith II; Promega, Madison, WI, USA) 5Ј-CCA GAG TCC CCT GTA CCC GC-3Ј (n = 20).
Treatment criteria included the presence of CMV disease, or persistence and severity of clinical features described earlier in the presence of viremia, viruria or DNAemia. Treatment of patients with active CMV infection consisted of ganciclovir 5 mg/kg body weight intravenously twice daily for 7 days, and then once daily for an additional 14 days. Intravenous immunoglobulins (IVIG) were also administered (0.5 g/kg/dose) for one or more doses depending on the severity of clinical features. Diag-nostic tests for CMV were repeated 2 to 3 weeks following the initiation of treatment.
Several variables were examined as potential risk factors for CMV infection. These included age, sex, myeloablative chemotherapy regimen, underlying malignancy, prophylactic use of acyclovir in Herpes simplex virus sero-positive patients, and CMV serology prior to autologous PBSCT. Contingency table (x   2   ) analyses were utilized to estimate the statistical significance of each discrete variable.
Results

Incidence and diagnosis
CMV was identified in the blood, urine or other submitted tissue samples in 26 patients (13%) with clinically suspicious signs and/or symptoms at a median of 45 days (range 15-87 days) following stem cell infusion. The median age of these patients was 45 years (range 14-61 years) which was not significantly different compared to the entire group of patients in this study (Table 1 ). Male to female ratio was 9:17. Seventeen patients had an underlying solid tumor whereas the remaining individuals had hematologic malignancies. Twenty patients who were seropositive for Herpes simplex had either received (n = 9) or were receiving (n = 11) prophylactic acyclovir when CMV was isolated. Only three of the 26 patients in whom CMV was identified were CMV sero-negative. Although every individual received corticosteroid therapy, only 17 of these 26 patients were receiving these agents when CMV was detected.
The occurrence of viral detection in various body fluids and tissues was as follows: viruria (n = 17), viremia (n = 1), viruria and viremia (n = 2), DNAemia (n = 2), viremia and DNAemia (n = 1). In two individuals with pneumonia and hypoxemia, CMV was cultured from broncho-alveolar lavage fluid. One of these patients also had coexistent viremia and viruria. One patient with persistent nausea, emesis and anorexia demonstrated histologic evidence of CMV infection from tissue obtained from a macroscopic gastric ulcer. Additionally, PCR analysis of this histologic specimen confirmed the presence of CMV. The overall incidence of viremia, DNAemia, viruria and CMV disease in our patients as detected by this strategy was 2.5%, 1.5%, 9% and 1.5%, respectively.
Clinical features, treatment and outcome
Clinical features and their positive predictive values are outlined in Table 2 . Twenty-three patients received ganciclovir for persistent clinical abnormalities. Two patients with mild constitutional symptoms and one individual with transient hemorrhagic cystitis did not require antiviral chemotherapy. Twenty-five patients received IVIG for a median of two doses (range 1-6). Both patients with CMV pneumonia died despite intubation and aggressive treatment. The single patient with CMV gastritis responded promptly to antiviral chemotherapy. Furthermore, the remaining 20 individuals who received ganciclovir therapy also responded promptly with complete resolution of their respective clinical abnormalities. Diagnostic tests for CMV were repeated after 2 to 3 weeks of treatment in these 20 patients and failed to detect the virus.
Risk factors
All 200 patients were included in the statistical analysis. Seropositivity for CMV was the only variable to achieve statistical significance (P Ͻ 0.001) in predicting an increased likelihood of subsequent detection of CMV in various body fluids and tissues after autologous PBSCT. All other potential risk factors such as age (P = 0.77), sex (P = 0.28), underlying malignancy (P = 0.66), specific myeloablative chemotherapy regimen (P = 0.74), and use of acyclovir for prophylaxis against Herpes simplex virus in sero-positive individuals (P = 0.11), failed to predict an increased likelihood of CMV viremia, viruria, DNAemia and disease.
Discussion
The incidence of CMV viremia and disease following autologous transplantation in most reported series is based on rigorous surveillance programs which include testing of blood, urine and throat swabs for the presence of CMV.
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Recently, PCR detection of CMV-DNA has also been utilized in such surveillance programs. Viral culture and antigen detection are positive in 7-45% of patients following autologous transplantation. [9] [10] [11] [12] [13] [14] [15] 17, 18 Detection of CMVDNAemia using PCR is also as high as 42% in these surveillance programs. 15 Although the incidence of CMV detection by these surveillance strategies approaches that observed in the allogeneic setting, the number of patients who actually require treatment is quite small.
14 It is apparent that following autologous BMT, surveillance programs identify a high percentage of clinically insignificant CMV viremia.
14 One group of investigators established treatment criteria in patients in whom CMV viremia had been detected by surveillance. These criteria consisted of fever, persistent thrombocytopenia, interstitial pneumonitis, upper gastrointestinal symptoms, and an unexplained elevation of hepatic transaminases. 14 In their study, only 14% of episodes of CMV viremia as detected by surveillance techniques following autologous transplantation required treat-ment with ganciclovir.
14 Cytomegalovirus is usually detected by surveillance at a median of 17-77 days following autologous BMT. 12, [14] [15] [16] The incidence of CMV detection and need for treatment appear to be similar following autologous BMT and PBSCT. [12] [13] [14] [15] [16] The incidence of clinically significant CMV viremia, viruria, DNAemia and disease was higher in our series of patients. It is possible that the use of highly dose-intense myeloablative chemotherapy regimens as well as corticosteroid administration for 6 weeks after autologous PBSCT may have resulted in marked immunosuppression. This could account for the greater number of patients with CMV viremia, viruria, DNAemia and disease presenting with signs and symptoms which required treatment in our series. It is important to note that the CMV-associated clinical features defined in this paper do not in and of themselves constitute evidence of CMV infection. Viruria alone is not considered sufficient to make a diagnosis of CMV infection. 19, 20 While the link between viruria/viremia and clinical symptoms is not firmly established, CMV testing was conducted only when a patient exhibited one or more of these CMV-associated clinical features. Simultaneous resolution of signs/ symptoms and viral excretion was noted following treatment in all cases, suggesting more than just a casual relationship.
The reported incidence of CMV pneumonia after autologous BMT ranges from 0.8% to 13.1%. 11, 15, 17, 18, [21] [22] [23] [24] [25] Risk factors include CMV seropositivity, and CMV viremia and viruria. 24 Mortality is high, ranging from 57% to 84%. 17, 18, [23] [24] [25] The incidence of CMV pneumonia in our patients was only 1% but proved to be fatal in both instances. Recently, a study investigated PCR detection of CMV in broncho-alveolar lavage specimens obtained 35 days following autologous PBSCT. 13 Unlike allogeneic recipients, 7 this form of surveillance failed to be useful following autologous PBSCT.
Recovery of immune function is more rapid after autologous PBSCT compared to autologous and allogeneic BMT. 26 The absolute number of CD3-positive lymphocytes recovers to normal by 17 days. 27 Moreover, CD8-positive cells, natural killer cells, and lymphokine-activated killer activity also reconstitute rapidly. [28] [29] [30] [31] Among CMV seropositive patients, CMV-specific CD8-positive lymphocytes and CD4-positive helper responses are restored in most patients within the first 3 months following autologous PBSCT. 32 Therefore, the immune system is capable of affording protection against CMV viremia, viruria, DNAemia and disease once the first 3 months after stem cell infusion have elapsed. None of our patients developed CMV viremia, viruria, DNAemia and/or disease beyond 3 months following autologous PBSCT.
The combined cost of shell vial assay, culture and PCR detection of CMV in blood, and shell vial assay and culture for CMV in urine is $341 in our institution. If surveillance testing for CMV had been employed on a weekly basis during the first 100 days following stem cell infusion in only our CMV seropositive patients (n = 84), the costs incurred would have totaled $429 660. Instead, when we tested patients based only on the presence of the CMVassociated symptoms outlined in this report regardless of their CMV serologic status, a total of 202 tests were performed at a cost of $68 882. Using such a strategy, the incidence of CMV disease was not significantly higher than that observed in series of patients undergoing surveillance, and most clinically apparent CMV viremias and virurias were detected and treated preemptively. It is noteworthy that reversal of neutrophil/lymphocyte ratio, unusual and persistent thrombocytopenia, unexplained elevation of hepatic transaminases and unexplained gastrointestinal symptoms were most likely to be associated with subsequent detection of CMV.
In conclusion, CMV viremia and disease are not uncommon causes of morbidity following autologous PBSCT using a truly myeloablative chemotherapy regimen. As already demonstrated in prior studies of patients undergoing autologous transplantation, 17 CMV seropositivity is the only significant risk factor predicting subsequent identification of CMV in body fluids and tissues. Individuals, especially those who are CMV sero-positive and exhibit the clinical features outlined in this report during the first 3 months after stem cell infusion, should be evaluated for CMV viremia, viruria, DNAemia and/or disease. Such a diagnostic strategy can obviate the need for surveillance programs which not only diagnose a high percentage of clinically insignificant CMV but can also prove quite costly. Once a diagnosis of CMV viremia, viruria, DNAemia and/or disease has been established, the use of antiviral chemotherapy in standard doses is successful in most patients. However, in some instances, CMV disease can be fatal despite aggressive measures, even following autologous PBSCT. In the allogeneic setting the use of preemptive therapy even in asymptomatic patients in whom the virus has been isolated from body fluids and tissues can be life saving. Therefore, our strategy can only be recommended in patients undergoing autologous peripheral blood stem cell transplantation.
